DAWN LOCEY: Open Payments
NPI 1063162758 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$951 in 52 payments from 14 companies in 2025. Trend: 2023 $877 · 2024 $1,078 · 2025 $951
Food & beverage: $951
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $210 |
| Janssen Pharmaceuticals, Inc | 2 | $148 |
| Vanda Pharmaceuticals Inc. | 6 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| Alkermes, Inc. | 5 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Corium, LLC | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
Products named: VRAYLAR, SPRAVATO, FANAPT, CAPLYTA, ARISTADA, REXULTI, Azstarys, ABILIFY ASIMTUFII.
Industry payments across ID — which companies pay providers there.
